AN2 Therapeutics, Inc., (ANTX) News

AN2 Therapeutics, Inc., (ANTX): $15.28

-0.19 (-1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter ANTX News Items

ANTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ANTX News From Around the Web

Below are the latest news stories about AN2 THERAPEUTICS INC that investors may wish to consider to help them evaluate ANTX as an investment opportunity.

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 4, 2022

Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Halozyme (HALO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AstraZeneca (AZN – Research Report), Halozyme (HALO – Research Report) and AN2 Therapeutics, Inc. (ANTX – Research Report) with bullish sentiments. AstraZeneca (AZN) In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on AstraZeneca, with a price target of $79.00. The company's shares closed last Friday at $62.77. According to TipRanks.

Catie Powers on TipRanks | November 14, 2022

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in TrialAwarded Contract from NIAID Valued Up to $17.8 Million to Advance Development of Epetraborole for Acute Systemic Melioidosis MENLO PARK, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infecti

Yahoo | November 9, 2022

AN2 Therapeutics to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. Details of the events are as follows: Stifel 2022 Healthcare Conference, November 15-17, 2022, New York, New York. Eric Easom, Co-Founder, President a

Yahoo | November 2, 2022

AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced one oral presentation and nine data poster presentations at the Infectious Disease Society of American (IDSA) IDWeek 2022 Conference from

Yahoo | October 19, 2022

AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese PatientsTreatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U.S., Two Countries with Highest Prevalence of MAC Lung DiseaseEpetraborole Granted Orphan Medicinal Product Designation in NTM Lung Disease in European Union MENLO PARK, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-

Yahoo | October 6, 2022

NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million

NIAID Agreement to Advance Development of Epetraborole for Acute Systemic MelioidosisNon-dilutive funding will drive synergies with existing epetraborole development program for NTM lung diseaseAward leverages AN2 Therapeutics expertise and commitment to address urgent unmet global health needsWork could help address U.S. biothreat pathogen MENLO PARK, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developin

Yahoo | September 29, 2022

AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, President and CEO will present at the H.C. Wainwright 24th Annual Global Investment Conference Details of the event is as follows: H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022 An on-demand

Yahoo | August 29, 2022

AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023Completed Enrollment in Phase 1 PK/Safety Study of Epetraborole in Healthy Volunteers in JapanPlan to Include Japanese Patients in EBO-301 Pivotal Phase 2/3 Trial; Gained Alignment with the PMDA on the Use of a Microbiological Primary Endpoint to Support Potential Registration in Japan MENLO PARK, Calif., Aug. 11,

Yahoo | August 11, 2022

What Type Of Shareholders Make Up AN2 Therapeutics, Inc.'s (NASDAQ:ANTX) Share Registry?

If you want to know who really controls AN2 Therapeutics, Inc. ( NASDAQ:ANTX ), then you'll have to look at the makeup...

Yahoo | August 8, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4723 seconds.